Peter Yunker boils down his advice for researchers wanting to commercialize their lab advances.
“You can’t go it alone,” said Yunker, an associate professor of physics at Georgia Tech.
In January, Yunker co-founded the biotechnology startup TopoDx LLC, with David Weiss, an Emory University School of Medicine researcher and director of the Emory Antibiotic Resistance Center, and Yogi Patel, a Georgia Tech alumnus with a background in business development and bioengineering.
“Researchers often think that they have a good commercialization idea to help people, but that alone does not guarantee success,” said Yunker. “Look for partners with complementary skills who understand aspects of the commercialization process that you don’t. Find mentors with business and scientific backgrounds in the specific industry you want to enter.”
TopoDx has developed a microbial test to identify antibiotic resistance and susceptibility rapidly and accurately. Current tests produce a result in three to five days. TopoDx’s approach can gain a result within four hours. Every hour counts in treating serious infections. Delays in accurate treatment can increase antibiotic resistance, which is a global challenge, causing up to 1 million deaths a year.
The company’s testing method was inspired by a fundamental biophysics project in Yunker’s lab. His team was interested in understanding how bacterial colonies behave. They tested white-light interferometry, a technology that can measure bacterial colonies down to the nanometer level.
Related Media
Peter Yunker, Georgia Tech: Heteroresistance AST
